.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Novartis
Cerilliant
Chinese Patent Office
Boehringer Ingelheim
QuintilesIMS
US Army
Federal Trade Commission
Chubb

Generated: December 12, 2017

DrugPatentWatch Database Preview

APTIVUS Drug Profile

« Back to Dashboard

Which patents cover Aptivus, and when can generic versions of Aptivus launch?

Aptivus is a drug marketed by Boehringer Ingelheim and is included in two NDAs. There are three patents protecting this drug.

This drug has one hundred and fifty-six patent family members in thirty-one countries and ten supplementary protection certificates in eight countries.

The generic ingredient in APTIVUS is tipranavir. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tipranavir profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Boehringer IngelheimAPTIVUStipranavirCAPSULE;ORAL021814-001Jun 22, 2005RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Boehringer IngelheimAPTIVUStipranavirSOLUTION;ORAL022292-001Jun 23, 2008RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Boehringer IngelheimAPTIVUStipranavirCAPSULE;ORAL021814-001Jun 22, 2005RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Boehringer IngelheimAPTIVUStipranavirCAPSULE;ORAL021814-001Jun 22, 2005RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Boehringer IngelheimAPTIVUStipranavirSOLUTION;ORAL022292-001Jun 23, 2008RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: APTIVUS

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,169,181 Compounds useful to treat retroviral infections► Subscribe
6,531,139 Self-emulsifying formulation for lipophilic compounds► Subscribe
6,121,313 Pharmaceutical composition in a form of self-emulsifying formulation for lipophilic compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: APTIVUS

Country Document Number Estimated Expiration
Hungary0002486► Subscribe
Canada2294031► Subscribe
Japan2002511099► Subscribe
Hungary0002440► Subscribe
Brazil9507615► Subscribe
China1261797► Subscribe
Hungary225160► Subscribe
Japan2002528502► Subscribe
Poland317061► Subscribe
HungaryT77601► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: APTIVUS

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0758327/01Switzerland► SubscribeFORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
2005008Lithuania► SubscribePRODCT NAME: TIPRANAVIRUM; REGISTRATION NO/DATE: EU/1/05/315/001 20051025
C/GB06/009United Kingdom► SubscribePRODUCT NAME: (R-(R*,R*))-N-(3-(1-(5,6-DIHYDRO-4-HYDROXY-2-OXO-6-(2-PHENYLETHYL)-6-PROPYL-2H-PYRAN-3-YL)PROPYL)PHENYL)-5-(TRIFLUOROMETHYL)-2-PYRIDINESULFONAMIDE OR A PHARMACEUTICAL SALT THEREOF = (TIPRANAVIR OR A PHARMACEUTICAL SALT THEREOF); REGISTERED: CH 57330 20050825; UK EU/1/05/315/001 20051025
0216Netherlands► Subscribe300216, 20150504, EXPIRES: 20200503
220Luxembourg► Subscribe91220, EXPIRES: 20200504
C034/2005Ireland► SubscribeSPC034/2005: 20061023, EXPIRES: 20200503
2005 00052Denmark► Subscribe
C0047France► SubscribePRODUCT NAME: TIPRANAVIR; REGISTRATION NO/DATE: EU/1/05/315/001 20051025
2005008,C0758327Lithuania► SubscribePRODUCT NAME: TIPRANAVIRUM; REGISTRATION NO/DATE: EU/1/05/315/001 20051025
00216Netherlands► SubscribePRODUCT NAME: TIPRANAVIR, DESGEWENST IN DE VORM VAN EEN; REGISTRATION NO/DATE: EU/1/05/315/001 20051025
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Covington
Merck
Dow
Teva
Queensland Health
Moodys
Express Scripts
Johnson and Johnson
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot